Anixa Biosciences
ANIX
19 hedge funds and large institutions have $4.89M invested in Anixa Biosciences in 2020 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
122% more capital invested
Capital invested by funds: $2.2M → $4.89M (+$2.69M)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
12% more funds holding
Funds holding: 17 → 19 (+2)
0.19% more ownership
Funds ownership: 6.6% → 6.79% (+0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$371K |
| 2 |
Millennium Management
New York
|
+$81.5K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$55.2K |
| 4 |
Morgan Stanley
New York
|
+$22.9K |
| 5 |
BlackRock
New York
|
+$17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$51K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$16.6K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$16K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$12K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$8.39K |
ANIX Hedge Fund Activity: Q2 2020 in Review
19 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q2 2020, worth a combined $4.89M — up 122% from $2.2M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ANIX positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was UBS Group, adding an estimated $371K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $51K sold.
- 19 institutional investors held Anixa Biosciences (ANIX) as of Q2 2020, up from 17 in Q1 2020.
- Funds reported $4.89M of Anixa Biosciences stock for Q2 2020, up 122% quarter-over-quarter.
- 5 funds opened new Anixa Biosciences positions in Q2 2020 and 3 closed out, a net change of +2 holders.
- The largest Anixa Biosciences buyer in Q2 2020 was UBS Group, an estimated $371K added.
- The largest Anixa Biosciences seller in Q2 2020 was Renaissance Technologies, an estimated $51K sold.
Based on aggregated 13F filings for Q2 2020.